Acumen Pharmaceuticals, Inc. Stock Issued During Period, Value, New Issues
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- Acumen Pharmaceuticals, Inc. stock issued during period, value, new issues for the quarter ending 2026-06-30 was -$12.00K.
- Acumen Pharmaceuticals, Inc. stock issued during period, value, new issues for the quarter ending 2026-03-31 was $35.45M.
- Acumen Pharmaceuticals, Inc. stock issued during period, value, new issues for the quarter ending 2024-12-31 was $0.00.
- Acumen Pharmaceuticals, Inc. stock issued during period, value, new issues for the quarter ending 2024-09-30 was $0.00, a 100.00% decline year-over-year.
- Acumen Pharmaceuticals, Inc. stock issued during period, value, new issues for fiscal 2024 was $7.94M, a 93.49% decline from fiscal 2023.
- Acumen Pharmaceuticals, Inc. stock issued during period, value, new issues for fiscal 2023 was $121.90M, a 3114.77% increase from fiscal 2022.
- Acumen Pharmaceuticals, Inc. stock issued during period, value, new issues for fiscal 2022 was $3.79M, a 97.75% decline from fiscal 2021.
- Acumen Pharmaceuticals, Inc. stock issued during period, value, new issues for fiscal 2021 was $168.56M.
| Period end | Stock Issued During Period, Value, New Issues 3 month | Stock Issued During Period, Value, New Issues 12 month |
|---|---|---|
| 2026-06-30 | -$12.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | |
| 2026-03-31 | $35.45M 10-Q · filed 2026-05-12 | |
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | $7.94M 10-K · filed 2026-03-26 |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $7.55M derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | $129.84M derived: sum of 4 quarters · filed 2025-08-12 |
| 2024-03-31 | $7.94M 10-Q · filed 2025-05-13 | |
| 2023-12-31 | -$390.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-27 | $121.90M 10-K · filed 2025-03-27 |
| 2023-09-30 | $122.29M 10-Q · filed 2024-11-12 | |
| 2022-12-31 | $3.79M 10-K · filed 2024-03-26 | |
| 2021-12-31 | -$3.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-27 | $168.56M 10-K · filed 2023-03-27 |
| 2021-09-30 | $168.56M 10-Q · filed 2022-11-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |
| Humacyte, Inc. (HUMA) | United States | $0.155B | -2.26 |
| Voyager Therapeutics, Inc. (VYGR) | United States | $0.173B | -1.99 |
| PRECISION BIOSCIENCES INC (DTIL) | United States | $0.175B | -3.95 |
| Coherus Oncology, Inc. (CHRS) | United States | $0.182B | -1.63 |
| Tenaya Therapeutics, Inc. (TNYA) | United States | $0.140B | -1.60 |
| Alpha Cognition Inc. (ACOG) | $0.185B | -6.77 | |
| Caribou Biosciences, Inc. (CRBU) | United States | $0.134B | -1.79 |
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B | |
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |